tapebrief
BDX · Q2 2026

BDX · Q3 2026 Earnings

Neutral

Becton Dickinson

Reported August 6, 2026

30-second summary

SENTIMENT: Constructive Q3 revenue grew 5.4% YoY to $4.98B (beat consensus of $4.89B by 1.9%) and adjusted EPS of $3.23 cleared consensus of $3.14 by 2.9%, comfortably above the ~$3.50 H2-implied cadence concern flagged last quarter — actually landing $0.27 below that shorthand but keeping the FY midpoint math intact because management raised the low end of FY26 adjusted EPS by $0.10 to $12.62–$12.72 (midpoint up to $12.67 from $12.62). Management now expects revenue growth "toward the high end" of the low-single-digit FY range, a meaningful step up in confidence from Q2's flat reaffirmation. Adjusted operating margin came in at 13.3% for the quarter (headline math; the ~25% adjusted anchor is a full-year framing) with gross margin at 46.5%.

Headline numbers

EPS

Q3 FY2026

$3.23

+2.9% vs est.

Revenue

Q3 FY2026

$4.98B

+5.4% YoY

+1.9% vs est.

Gross margin

Q3 FY2026

46.5%

Free cash flow

Q3 FY2026

$1.73B

Operating margin

Q3 FY2026

13.3%

Key financials

Q3 FY2026
MetricQ3 FY2026Q3 FY2025YoYQ2 FY2026QoQ
Revenue$4.98B$5.51B-9.5%$4.71B+5.7%
EPS$3.23$3.68-12.2%$2.90+11.4%
Gross margin46.5%47.8%-130bps45.7%+80bps
Operating margin13.3%16.0%-270bps2.0%+1130bps
Free cash flow$1.73B——$1.09B+57.8%

Guidance

Company raised FY2026 EPS guidance low end by $0.10 while holding Q3 guidance intact; Q3 results beat on both revenue and EPS.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ3 FY2026Low single-digit plus YoY growth$4.983B (5.4% YoY growth)In-line with low single-digit plus YoY rangeBeat
Non-GAAP EPSQ3 FY2026Embedded in full-year range$3.23+2.9% above consensus estimate of $3.14Beat

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted Diluted EPS
FY2026
$12.52 to $12.72$12.62 to $12.72Low end raised $0.10 (from $12.52 to $12.62); high end reaffirmedRaised

Segment KPIs

Q3 FY2026
SegmentQ3 FY2026Q3 FY2025YoY
Medical Essentials$1.675B—+4.5%
Connected Care$1.224B—+4.9%
BioPharma Systems$0.67B—+6.6%
Interventional$1.414B—+6.4%
Medication Delivery Solutions Revenue$1.164 billion——
Specimen Management Revenue$0.511 billion——
Medication Management Solutions Revenue$0.915 billion——
Advanced Patient Monitoring Revenue$0.309 billion——
Peripheral Intervention Revenue$0.552 billion——

Other KPIs

Q3 FY2026
SegmentQ3 FY2026Q3 FY2025YoY
United States$3.081B$3.181B-3.1%
International$1.902B$2.328B-18.3%
Adjusted Operating MarginNot separately disclosed in press release——
Cash from Continuing Operations (9M YTD)$2.1 billion——
Free Cash Flow Margin (9M YTD)12.2%——

Management tone

No transcript available for Q3 — tone commentary is inferred from the press release language shift only.

The material shift is quantifiable in two press-release phrases: last quarter management "reaffirmed" the low-single-digit FY revenue range; this quarter it expects growth "toward the high end of its range." That is not a numerical guidance change — the range is unchanged — but it is a directional narrowing that signals management's central-case internal number has moved up. Paired with the +$0.10 low-end EPS raise, the posture is de-risking the FY landing while nudging the growth mix upward.

The second press-release addition is "strong momentum across our key growth platforms." Prior quarters called out specific engines (Interventional, APM, Alaris competitive funnel) but stopped short of a broad-based momentum claim. The BioPharma Systems acceleration to +6.6% reported — the segment that carried the vaccine drag all year — is the concrete evidence behind the phrase.

Multi-quarter arc for EPS raises: Q1 recast → Q2 +$0.17 low / +$0.07 high / +$0.12 mid → Q3 +$0.10 low / unchanged high / +$0.05 mid. The pattern is decelerating raises with the high end untouched all year — consistent with a management team that is banking beats into the low end rather than reaching for an upside surprise at the ceiling. Investors reading the tape as "guide-through" should note this is the third consecutive quarter of raises without a high-end move.

Answers to last quarter's watch list

Q3 adjusted EPS cadence — Q3 non-GAAP EPS landed at $3.23, below the informal ~$3.50 threshold implied by the H1/FY math. However, the FY midpoint was raised by $0.05 (to $12.67 from $12.62), and 9M YTD EPS is now $8.61 ($5.38 H1 + $3.23 Q3) vs. the new midpoint of $12.67, implying Q4 needs ~$4.06 to hit the midpoint — a Q4-loaded cadence that does re-introduce some back-half-heroics risk, but with the low end raised, the floor is more secure. Status: Continue monitoring
El Paso ChloroPrep remediation timing — the press release does not call out any residual ChloroPrep shipment hold or Medical Essentials disruption; the segment printed +4.5%, in line with Q2's +4.7%. Absent transcript detail, no explicit resolution was disclosed but the segment result suggests no material scar. Status: Continue monitoring
Adjusted operating margin trajectory to ~25% — the press release does not break out Q3 adjusted operating margin separately; only the GAAP 13.3% is available. Without the adjusted figure disclosed, the H2 step-up path cannot be assessed from this print. Status: Continue monitoring
BioPharma Systems vaccine lap — resolved sharply positive. Reported segment growth accelerated to +6.6% from +2.5% in Q2, consistent with the thesis that biologics (double-digit growth, ~55% of segment mix) would lift reported growth once the vaccine base normalized. Status: Resolved positively
Capital deployment cadence post-ASR — the press release excerpts do not disclose incremental buyback authorization or open-market activity beyond the completed $2B ASR. Status: Continue monitoring
Alaris competitive funnel conversion — MMS Q3 revenue of $915M is disclosed but the press release does not quantify Alaris share gains for the quarter. Status: Continue monitoring

What to watch into next quarter

Q4 adjusted EPS vs. implied ~$4.06 — the raised midpoint of $12.67 minus 9M YTD $8.61 leaves a Q4 requirement of ~$4.06, well above the ~$3.23 Q3 print. This is a Q4-loaded landing, and any disruption would force a mid-year credibility test. The low-end $12.62 requires ~$4.01 — no relief.

BioPharma Systems durability — whether the Q3 acceleration to +6.6% is a vaccine-lap one-off or the start of the biologics-dominant run rate. A print of +5%+ in Q4 would confirm the structural shift; back to sub-3% would suggest Q3 was a comp benefit.

Adjusted operating margin disclosure in the transcript — the FY ~25% adjusted anchor requires a clear H2 step-up from Q2's 24.2%. Watch for the Q3 adjusted operating margin figure once the transcript / 10-Q lands, and whether Q4 needs to carry the balance.

International trajectory — the U.S./International gap widened this quarter (+6.9% vs. +3.2%). Watch whether International stabilizes or continues to decelerate as China VBP approaches its 80% category coverage endpoint.

Capital deployment update — a full quarter has now passed since the $2B ASR completion. Any incremental authorization, or absence thereof, will indicate whether management still views the stock as materially undervalued at current levels.

FY guide high end — three consecutive quarters of low-end-only raises. A high-end move in Q4 (or a fresh FY27 frame that starts above the FY26 high end) would signal genuine upside confidence; another low-end-only raise would confirm the de-risking posture.

Sources

  1. BDX Q3 FY2026 press release (filed 2026-08-06): https://www.sec.gov/Archives/edgar/data/10795/000162828026053790/ex9916302026.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.